Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

-   $17.5 million upfront proceeds with up to an additional $175 million of proceeds upon the exercise of warrants
-   Initial capital funds expansion of Phase 1b trial in severe alcohol-associated hepatitis and extends cash runway
-   Phase Ib data in expanded study expected in 1H 2025

Read more at globenewswire.com